Research Peptide Contamination Risk

Research-grade peptide supply chains do not enforce the contamination controls that pharmaceutical-grade supply chains do. This page describes the categories of risk at a literacy level — not at a practical-use level.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

What can be in a vial besides the intended peptide

• Synthesis by-products (truncated sequences, racemised residues).
• Residual solvents (DMF, DCM, TFA from cleavage and lyophilisation).
• Heavy metals from synthesis equipment.
• Endotoxin from bacterial contamination during processing.
• Microbial contamination if aseptic handling is incomplete.
• Excipients not declared on the label.

Why these are not visible to the buyer

A vial of white powder looks the same regardless of what is in it. Standard COAs report identity and purity by HPLC; they typically do not report endotoxin, microbial counts, or residual solvent profiles. Even an honest COA leaves the contamination question largely unanswered.

Counterfeit supply chains

At the grey-market end of the supply chain, vials may be relabelled, underdosed, mislabelled, or contain a different compound entirely. See: counterfeit supply.

What this means for self-administration

PeptideStacks does not provide self-administration guidance. The contamination picture above is one of several independent reasons why a research-grade vial is not a substitute for a pharmaceutical product administered under clinical oversight. See: why research grade is not safe.